The performance of companies tied to Viagra's past presents a challenging investment landscape. While the initial surge generated substantial returns , generic alternatives have significantly eroded revenue. Investing in related pharmaceutical businesses now requires a discerning assessment of intellectual property rights , evolving healthcare chan